Key facts
- Bardy Diagnostics’s last known valuation is $375.0M (Aug 2021).
- It has raised $10.5M across 4 recorded rounds; the latest was Early Stage VC ($12.5M) in Feb 2020.
- Bardy Diagnostics has filed 5 Form Ds with the SEC since 2018, most recently Mar 2020 ( sold to 1 investors).
- Status: Acquired/Merged (Operating Subsidiary).
- ·Post-money valuations for all 4 rounds
- ·Watchlist + deal alerts for Bardy Diagnostics
Funding rounds
4 roundsAbout Bardy Diagnostics
Developer of ambulatory cardiac monitoring devices designed to monitor and diagnose arrhythmia. The company's lightweight device is placed in the center of the chest, directly over the heart, for ECG and P-wave signal collection, enabling medical practitioners to track cardiac patients' heart rates remotely and improve decision-making.
- Sector
- Healthcare
- HQ
- Bellevue, WA, United States
- Founded
- 2013
- Employees
- 175
- Website
- bardydx.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Bardy Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bardy Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bardy Diagnostics in its N-PORT filings yet. We sweep new filings monthly.